Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Misses Estimates By $0.01 EPS

Sana Biotechnology (NASDAQ:SANA) released its quarterly earnings data on Monday. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01), Zacks reports.

Sana Biotechnology Stock Performance

SANA traded down $0.16 during midday trading on Monday, hitting $2.77. The company had a trading volume of 4,012,620 shares, compared to its average volume of 2,981,885. The company has a market capitalization of $618.46 million, a PE ratio of -1.98 and a beta of 1.63. Sana Biotechnology has a twelve month low of $1.52 and a twelve month high of $10.50. The firm’s 50-day simple moving average is $3.03 and its 200-day simple moving average is $3.25.

Insider Buying and Selling at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 31.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on SANA shares. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday. They set a “buy” rating and a $7.00 price objective for the company. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright lifted their price target on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $12.25.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.